Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid, appearance varies by batch |
| Solubility | Soluble in water | Also dissolves in aqueous buffer; side chain alters behavior |
| Storage, dry powder | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Storage, in solution | 2 to 8 degrees Celsius | Short term only; avoid repeated freeze-thaw |
| Primary assay | Reversed-phase HPLC | Frequently paired with mass spectrometry |
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
X.906|ISO/IEC 19793: Information technology - Open distributed processing - Use of UML for ODP system specifications". This document (usually referred to as UML4ODP) defines use of the Unified Modeling Language 2 (UML 2; ISO/IEC 19505), for expressing the specifications of open distributed systems in terms of the viewpoint specifications defined by the RM-ODP. It defines a set of UML Profiles, one for each viewpoint language and one to express the correspondences between viewpoints, and an approach for structuring them according to the RM-ODP principles. The purpose of "UML4ODP" to allow ODP modelers to use the UML notation for expressing their ODP specifications in a standard graphical way; to allow UML modelers to use the RM-ODP concepts and mechanisms to structure their large UML system specifications according to a mature and standard proposal; and to allow UML tools to be used to process viewpoint specifications, thus facilitating the software design process and the enterprise architecture specification of large software systems. In addition, ITU-T Rec. X.906 | ISO/IEC 19793 enables the seamless integration of the RM-ODP enterprise architecture framework with the Model-Driven Architecture (MDA) initiative from the OMG, and with the service-oriented architecture (SOA).
Dividing a compound mixture into equal portions Coupling one different building block (BB) to each portion Pooling and thoroughly mixing the portions The original method is based on the solid-phase synthesis of Merrifield The procedure is illustrated in the figure by the flowing diagram showing of a two-cycle synthesis using the same three BBs in both cycles. Choosing the solid phase method in the S&P synthesis is reasonable since otherwise removal of the by-products from the mixture of compounds would be very difficult.
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. Life-threatening adverse reactions have been observed.
== Uses == The stilbenoid oxyresveratrol can be isolated from the heartwood of Artocarpus lacucha as well as in Puag Haad, the light brown powder obtained from the aqueous extract of the wood chips of A. lakoocha by boiling, then slow evaporation, followed by cooling. This traditional drug is effective against the intestinal fluke Haplorchis taichui or against taeniasis. Experiments have shown that the heme-peroxidase enzyme from Artocarpus lacucha has the ability to protect against oxidative damage in vitro and possesses wound healing properties. This stable enzyme also has anti-inflammatory properties, making it a potential candidate for use in biotechnological and industrial applications.
This is a list of biochemists. It should include those who have been important to the development or practice of biochemistry. Their research or applications have made significant contributions in the area of basic or applied biochemistry.
Sources: en.wikipedia.org
The picture is elaborately framed by five successive decorative borders with naturalistic vine rinceau, suggestive of Roman art. The colors of the murals are various shades of brown, with smatterings of light green, but no blue, defining the so-called "orange and green" style. The center of the ceiling has motifs of the sun and moon, two monks, and a bird flying with a human figure in its claws. The sides of the ceiling are composed of diamond-shaped mountains, around which are naturalistic motifs of humans, animals, lakes and trees, a possibly Near-Eastern design which was generally adopted in later caves at Kizil. A band of fantastic animals separated the ceiling from the side walls. The general style appears to be early, and possibly derived from Kashmir and Cave 24 at Bamiyan. The lunettes bordering the ceiling display ornate Buddhist scenes. The right lunette is difficult to identify, but seems to represent a king or a Bodhisattava bending towards a warrior figure. The bottom portion shows a palatial scene, with a figure on a couch surrounded by devatas. The left lunette shows the Buddha of the future Maitreya in the Tusita Heaven. Below this is a depiction of Mount Sumeru surrounding by various Nagas, figures of devotees, and animals. Small figures of kneeling devotees in tunics, about 40 centimeters (15 inches) tall, some armed with a dagger, appear next to the left and right corners of the back-wall mural: probably noble and wealthy Kuchean donors of the 4th century CE. One of the donors holds three burning incense cones.
Astatine is the rarest naturally occurring element. The total amount of astatine in the Earth's crust (quoted mass 2.36 × 1025 grams) is estimated by some to be less than one gram at any given time. Other sources estimate the amount of ephemeral astatine, present on earth at any given moment, to be up to one ounce (about 28 grams). Any astatine present at the formation of the Earth has long since disappeared; the four naturally occurring isotopes (astatine-215, -217, -218 and -219) are instead continuously produced as a result of the decay of radioactive thorium and uranium ores, and trace quantities of neptunium-237. The landmass of North and South America combined, to a depth of 16 kilometers (10 miles), contains only about one trillion astatine-215 atoms at any given time (around 3.5 × 10−10 grams). Astatine-217 is produced via the radioactive decay of neptunium-237. Primordial remnants of the latter isotope—due to its relatively short half-life of 2.14 million years—are no longer present on Earth. However, trace amounts occur naturally as a product of transmutation reactions in uranium ores. Astatine-218 was the first astatine isotope discovered in nature. Astatine-219, with a half-life of 56 seconds, is the longest lived of the naturally occurring isotopes. Isotopes of astatine are sometimes not listed as naturally occurring because of misconceptions that there are no such isotopes, or discrepancies in the literature. Astatine-216 has been counted as a naturally occurring isotope but reports of its observation (which were described as doubtful) have not been confirmed.
Duterte's socioeconomic policies, referred to as DuterteNomics, include tax reform, infrastructure development, social protection programs, and other policies to promote economic growth and human development in the country. Finance Secretary Carlos Dominguez III has said that the government required what he describes as an "audacious" economic strategy in order for the Philippines to "catch up with its more vibrant neighbors" by 2022 and help it achieve high-income economy status within a generation. The term DuterteNomics was coined to describe the economic policy of the Duterte administration. Duterte initiated liberal economic reforms to attract foreign investors. In March 2022, he signed Republic Act No. 11647 which amended the Foreign Investment Act of 1991, effectively relaxing restrictions on foreign investments by allowing foreigners to invest in a local enterprise up to 100% of its capital. He signed Republic Act No. 11659, amending the 85-year-old Public Service Act, allowing full foreign ownership of public services, which include airports, expressways, railways, telecommunications, and shipping industries, in the country. Duterte reformed the country's tax system in an effort to make the country's tax system fairer, simpler, and more efficient.
=== Sources === Chapple, Christopher Key (1993), Nonviolence to Animals, Earth, and Self in Asian Traditions, State University of New York Press Cort, John E., ed. (1998), Open Boundaries: Jain Communities and Cultures in Indian History, SUNY Press, ISBN 0-7914-3785-X Cort, John E. (2001a), Jains in the World: Religious Values and Ideology in India, Oxford University Press, ISBN 978-0-19-513234-2 Dundas, Paul (2002) [1992], The Jains (Second ed.), London and New York: Routledge, ISBN 978-0-415-26605-5 Jaini, Padmanabh S. (1998) [1979], The Jain Path of Purification, Delhi: Motilal Banarsidass, ISBN 978-81-208-1578-0 Laidlaw, James (1995), Riches and Renunciation. Religion, economy, and society among the Jains, Oxford, ISBN 978-0-19-828031-6 Sangave, Vilas Adinath (1980), Jain Community: A Social Survey (2nd ed.), Bombay: Popular Prakashan, ISBN 978-0-317-12346-3 Shah, Umakant Premanand (1987), Jaina-rūpa-maṇḍana: Jaina iconography, Abhinav Publications, ISBN 81-7017-208-X Vallely, Anne (2002), Guardians of the Transcendent: An Ethnography of a Jain Ascetic Community, University of Toronto Press, ISBN 978-0-8020-8415-6 Wiley, Kristi L. (2009) [1949], The A to Z of Jainism, vol. 38, Scarecrow Press, ISBN 978-0-8108-6337-8
Additionally a rapid separation approach was published in the Journal of Chromatography A in 2007. The process uses high-capacity high-speed countercurrent chromatography (high-capacity HSCCC). Through this method honokiol can be separated and purified to above 98% purity with a high yield in under an hour.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.
Dry powder is usually kept at minus 20 degrees Celsius or below in a sealed, desiccated container. Once dissolved, material is refrigerated and used quickly. These conventions apply to research-grade peptides generally, not to a specific marketed product.
Chromatography separates components but does not confirm what they are. Mass spectrometry assigns a mass to each peak, which identifies the target peptide and flags modifications such as oxidation or truncation. The two techniques together give both a quantity and an identity check.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.